Podcasts about medicine division

Join us in this episode as we explore the groundbreaking Medication for Addiction Treatment (MAT) Order Set at UC San Diego Health. This innovative system helped them earn CHIME's top "Digital Health Most Wired" Level 10 status in 2024. What You'll Learn: The motivation behind the creation of UC San Diego's MAT Order Set. How interdisciplinary collaboration led to a comprehensive care model. Implementation details and integration of additional screenings. Data demonstrating reduced hospital readmissions and increased buprenorphine usage. Challenges and lessons learned during the implementation process. Educational impacts on medical resident training and future directions. MODERATOR: Gregory R. Polston, MD Clinical informaticist, Associate Medical Director, Center for Pain Medicine, UC San Diego Health Section Chief of the pain service, VA Medical Center La JollaBio: Dr. Polston is a board-certified anesthesiologist with expertise in pain medicine and clinical informatics at UC San Diego Health. He serves as Associate Medical Director at the Center for Pain Medicine and Section Chief of the pain service at the VA Medical Center La Jolla. Dr. Polston specializes in opioids and risk monitoring for acute and chronic pain, promoting a comprehensive approach to pain management that involves patient engagement and diverse therapeutic methods. His research focuses on chronic opioid therapy, placebos, and electronic medical records.GUEST: Laura Bamford, MD, MSCE Clinical Professor of Medicine Division of Infectious Diseases and Global Public Health Clinical Professor of Medicine Medical Director Owen Clinic Co-Director Clinical Investigations Core San Diego Center for AIDS Research Division of Infectious Diseases and Global Public Health University of California, San Diego Bio: Laura completed her Internal Medicine residency at Columbia University Medical Center and Infectious Diseases fellowship at the Hospital of the University of Pennsylvania where she also received a Master of Science in Clinical Epidemiology. She's a Clinical Professor of Medicine in the Division of Infectious Diseases and Global Public Health and Medical Director of the HIV Medicine Owen Clinic. Her clinical and research interests include HIV and HCV treatment and prevention in people who use drugs. She's passionate about delivering patient-centered care and research with a low barrier and harm reduction approach. With funding from the Ryan White HIV/AIDS Program Part F Special Projects of National Significance, she founded a HIV primary care clinic in 2013 within Philadelphia's syringe service program. She was selected as a member of the Mayor's Task Force to Combat the Opioid Epidemic in Philadelphia in 2017 and testified in federal court in 2019 as a fact witness on behalf of Safehouse, Philadelphia's proposed opioid overdose prevention site. She currently provides substance use disorder treatment integrated into HIV primary care at Owen Clinic and is a member of the UCSD Addiction Medicine/Pain Medicine Committee and the UCSD Opioid Use Disorder Task Force. She also serves as the coordinator of the newly mandated substance use disorder rotation at UCSD for all Internal Medicine residents and was recently appointed to the Board of Directors at Stepping Stone San Diego which specializes in substance use treatment in the LGBTQ+ community. GUEST: Carla Marienfeld, MD, DFAPA, FASAM Clinical Professor, University of California, San Diego Bio: Carla Marienfeld, MD, DFAPA, FASAM, Clinical Professor at UC San Diego, Medical Director Substance Treatment and Recovery (STAR) Program, Program Director UC San Diego Addiction Psychiatry Fellowship is board-certified in psychiatry, addiction psychiatry, and addiction medicine. She has authored over four dozen publications and edited four addiction treatment related books. 

Dr. Shannon Westin and her guest, Dr. Breelyn Wilky, discuss the JCO article, "“Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas." TRANSCRIPT  Shannon Westin: Hello, everyone, and welcome to another episode of JCO After Hours, the podcast where we get in depth on research that has been published in the Journal of Clinical Oncology. I am your host, Gynecologic Oncologist and Social Media Consultant Editor of the JCO, Shannon Westin. I serve here from the University of Texas MD Anderson Cancer Center. And I am so excited to welcome Dr. Breelyn Wilky. She's an Associate Professor and the Director of Sarcoma Medical Oncology in the Department of Medicine Division of Medical Oncology, and the Cheryl Bennett & McNeilly family endowed chair in Sarcoma Research, the Deputy Associate Director of Clinical research at the University of Colorado Cancer Center. Welcome. Dr. Breelyn Wilky: Thank you so much. I'm delighted to be here. Shannon Westin: And with all those titles, I'm super impressed that she was able to complete the manuscript that we're going to discuss today, which is “Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas.” And this was published in the JCO on January 27, 2025. And please note, our participants do not have any conflicts of interest. So this is exciting. Let's first level set. Can you review with us just the current state of sarcoma incidents, survival outcomes, that kind of thing so we all know where we're starting? Dr. Breelyn Wilky: Yes. So, you know, sarcomas are really, I like to call them the black box cancer type. And the big thing is that there's really more than a hundred different kinds of sarcomas, which collectively altogether make up only 1% of adult cancers. And so we talk about these as being bone and soft tissue tumors, but really, the heterogeneity is just incredible. You're talking maybe 10,000 to 12,000 new cases of soft tissue sarcoma per year, which is pretty rare in the grand scheme of things. And the trouble with these is that while you can cure sarcomas if you find them early and they're localized, when they metastasize and spread and are not resectable, we're looking at median overall survivals of really only 12 to 18 months, even, you know, with our best therapies that we have. So, really there's just a dire need for new treatments for this really tough group of diseases. Shannon Westin: Yeah, I agree. I'm a gynecologic oncologist, and we have our little subset of sarcomas that I know there's a little bit out of every one. So I'm really excited to pull this manuscript as one of our podcasts offerings because I think we're all seeing these patients in the clinic and certainly our listeners that have sarcoma or have family members with sarcoma, this is so good to have a real focus on a rare group of tumors that have been a little bit lumped together. Now, with that being said, I know this is such a heterogeneous population, but can you briefly overview a little bit around the standard of care for treatment of recurrent sarcomas? Dr. Breelyn Wilky: We have actually been using the same drugs really since about the 1970s, and up until very recently, nothing had really challenged doxorubicin, the old ‘red devil', like we used to call it. And this has been the mainstay of treatment for metastatic sarcomas and really used across the board. In the GYN literature, for uterine leiomyosarcoma, we did see some promising activity with the combination of doxorubicin and trabectedin coming out of the French group. But, except for that study, no combination therapy or new drug has been proven better in terms of overall survival compared to doxorubicin monotherapy, really over 40, 50 years. So it's definitely a tough situation. Now, we do have other drugs that we use, so most patients will wind up getting doxorubicin-based therapy. There's a couple of other regimens that we'll reach to, like gemcitabine docetaxel. And once you get into the specific subtypes, we have some approvals in liposarcomas and leiomyosarcomas for some other drugs. But really the median progression for survival for most of these regimens is somewhere four to six months. And response rates typically are somewhere like 10%, 15% for most of these. So it's really just a very tough field and a tough group of patients to try to make an impact for. Shannon Westin: So let's talk a little bit more kind of getting focused on what you've studied here. What's been the role of immunotherapy thus far in the treatment of sarcomas maybe prior to this particular study? Dr. Breelyn Wilky: Clearly, we all know that immune therapy has just changed cancer care forever over the last few years for so many different types of cancers and diseases like melanoma and renal cell and lung cancer have just been transformed by checkpoint inhibitors specifically directed against PD-1 or CTLA-4 or both. And so, of course, you know, sarcoma docs we're super excited to try to see if these might potentially have activity in our tumors as well. I never had seen myself in my career getting into immunotherapy until I was able to run an investigator-initiated study during my role in Miami, where we combined pembrolizumab, so PD-1 inhibitor, with axitinib which was a pan-VEGF inhibitor. And lo and behold, like I had patients that I was seeing responses when other treatments, all those chemotherapies I was just talking about had failed. And one of my first patients I treated was about a 60-year-old lady with something called cutaneous angiosarcoma. So this is a blood vessel sarcoma all over her face. And we had treated her with 10 different therapies, all the chemotherapy regimens, targeted therapies, clinical trials, and nothing was working. But I put her on a phase 1 trial with a baby dose of CTLA-4 and this woman had a complete response. And so for me, once I saw it work in even just those couple of patients, like that was nothing that we'd ever seen with our chemotherapy regimens. And so that sort of shifted my career towards really focusing on this, and this is about the time where some of the studies started to come out for sarcomas. And the take home with sarcoma is about 20% of sarcomas have this sort of immune hot physiology. So what that basically means is if you look at gene expression of immune related gene signatures, or you look for infiltrating T-cells, sort of the SWAT team of our immune system, like you can find those in the tumors. And it's sort of evidence that the immune system had some clue for that 20% of patients that this was a foreign tumor and that it should be attacking it and maybe just needed a little help. But globally, about 80% of sarcomas are these immune cold tumors, which means the immune system has no clue that these things are even a threat. And there's almost no immune activation, very, very few antigens. In other cancer types, high neoantigens or tumor antigens help the immune system work better. And so that basically goes with what we've seen with trials of PD-1 or CTLA-4 blockade. About 20% of sarcomas, with some exceptions, can respond. But really 80% across the board, you're stuck, you just can't get them to be recognized. And so that's where I think this data is so interesting is there's some signals of activity in these immune cold tumors which, at least historically with the trials we've done so far, we really haven't seen that with sort of the traditional checkpoints. Shannon Westin: So I think now this is a great time to maybe talk about the study design in general, the eligibility and just give us kind of a run through of that. Dr. Breelyn Wilky: So this trial was a phase 1 trial of a drug called botensilimab, which is a next generation CTLA-4 directed immune modulator. So what makes botensilimab different is that the CTLA-4 end is very similar to other CTLA-4 inhibitors that are out there, but it's been engineered on the back end of the molecule that binds to Fc gamma receptors to basically bind tighter with higher affinity. And what this translates to in laboratory models and increasingly now in patients is it does a better job of priming, of educating our T cells, our, again, these highly intelligent antigen specific cells, but also natural killer cells. It does a better job of sort of educating those. It helps to activate macrophages and other supporting actors in the immune response. And so the idea here is that there's evidence that botensilimab may do a better job at creating new responses in immune cold tumors. The study combined either botensilimab as monotherapy or in combination with a PD-1 inhibitor called balstilimab. And this was all comers, really a variety of tumor types. And to date I think we're close to about 500 patients with a variety of solid tumors that have been accrued to this study, this C-800-01 phase 1 trial. This paper reports on the sarcoma patients that were enrolled as part of this study. And so, again, given what I've told you about sarcomas being really immune cold, we were just so excited to have the opportunity to enroll on a next generation immune therapy for these tumors that really we were running into roadblocks trying to use immunotherapy previously. Shannon Westin: It's a very compelling idea and I'm so excited for you to tell people what you found. I think first things first, it was an early phase trial. So why don't we talk a little bit about the safety of the regimen. Was there anything that you didn't expect? Dr. Breelyn Wilky: Right. So similar to other checkpoint inhibitors, you know, the idea is that these drugs can cause immune mediated toxicities, right? So essentially you're revving up the immune system and it can sometimes get a bit confused and start attacking our normal cells, our normal organs, leading to essentially any number of toxicities of basically head to toe, something can get inflamed and you can develop a toxicity from that. So the key take homes with this particular drug with, botensilimab with balstilimab, we saw colitis was sort of the primary immune mediated toxicity and it was about a third of patients, give or take. It happens and it can be aggressive and needs to be managed aggressively. And you know, one of the things that we learned very quickly taking part in this study is how important it is that as soon as patients start to get diarrhea, immunosuppression gets on board. So steroids, early use of TNF alpha blockade, so infliximab for example, if we jumped on it quickly and we recognized it and we got the patients treated, it would resolve fairly quickly and even some patients could remain on treatment. So I think that was sort of the first take home is “Okay if you get colitis, you treat it fast, you treat it early and you can still have patients not only recover, which essentially everybody recovered from this colitis and then being able to continue on treatment and still have their anti-tumor responses.” So that's the first point. The second thing that was really interesting is part of the engineering of botensilimab on the back end of the molecule, it's been designed to decrease complement binding and it's thought that that triggers some of these other toxicities that we've seen with prior CTLA-4 inhibitors like pneumonitis or hypophysitis. We actually don't see that with botensilimab. So there's sort of this selective toxicity that may reflect the design of the molecule. But overall the treatment was, we didn't see any new safety signals that were outside of what we would expect in class. And colitis was sort of the dominant thing that we had to be ready for and ready to manage. Shannon Westin: We've been doing it for a while now, so we kind of know what to do and we can act quickly and really try to mitigate and avoid some of the major toxicities. So that's great that that was what was reflected in what you found. And then of course I think: What about the efficacy?” Right. This is what we care about as practitioners, as patients. Does it work and are there any subtypes that seem to benefit the most from this combination? Dr. Breelyn Wilky: Right. So for the sarcoma patients, we treated 64 patients and 52 of those patients were evaluable for efficacy. So a decent size group of patients in sarcomas, where, you know, typically our trials are pretty small, they're very rare, but we had 52 evaluable with at least one post baseline scan. So that was our criteria. And basically we saw across all of the patients, and keep in mind, these are heavily pre-treated patients, as you mentioned, so a median of 3 prior lines of therapy, so most of these patients had had chemotherapies and then about 20% had also had prior immunotherapy as well. So PD-1 treatments or so on. The overall response rate by RECIST was 19.2% for all of the evaluable patients. And then with iRECIST, which is sort of that immune adapted response criteria that allows for early pseudo progression, we actually had another patient who did have that. And so that response rate was 21.2%. Overall, we were really excited to see this in a heavily pre-treated group of patients. But what was really exciting to me was when we looked at the subset of patients that had angiosarcoma, that blood vessel tumor I was talking about earlier with my other patient. So angios come in two flavors. One is this sort of cutaneous type, or meaning involving the skin that has a UV signature, a UV damage signature, very similar to melanoma. So these tumors tend to have a high mutation burden. And oftentimes there is a track record that we've seen responses with immunotherapy in cutaneous angiosarcomas. But the other group that we deal with is called visceral angiosarcomas. And so these are totally different biologically. These are often driven by mutations in MYC or KDR amplification, and they arise in organs, so primary breast angiosarcoma, not associated with radiation, or they can arise in the liver or the spleen or an extremity. So these are very, very different tumors, and the visceral ones almost never historically have responded to checkpoint inhibitors. So we had 18 patients with angio split - 9 with cutaneous, 9 with visceral. And we were just blown away because the response rate for that group was 27.8%. And if you looked at the responses between the hot ones and the cold ones, it was almost equal and a little bit better in the visceral. So we had a 33% response rate in visceral angiosarcoma, which is crazy, historically speaking, and about 20% again in the cutaneous angios. So for a disease where visceral angio gets treated with chemotherapy, might respond initially, but then rapidly progresses - like these people go through multiple lines of therapy - to have a third of patients responding, and then some of those responses were durable. Our median duration of response for the study was 21.7 months, which is just nuts for sarcomas where we just don't see those sorts of long term benefits with the drugs that we have. So I think those are kind of the two main things. There were other subtypes that had clinical benefit and responses as well in d-diff liposarcoma, soft tissue leiomyosarcoma, which are again thought to be fairly cold immune subtypes. So just really exciting to kind of see responses we hadn't expected in a very challenging group of tumors. Shannon Westin: We see all these patients and we have patients that respond so well to immunotherapy with other histotypes. And so it's so exciting to see an option for these really hard to treat tumors that our patients struggle with. So this is so, so very exciting. I wanted to make mention, you know, I was really impressed with the amount of translational work you were able to do in this early phase study. So do you want to review just maybe a few of the key findings that you guys discovered? Dr. Breelyn Wilky: It's always great. I'm a translational researcher at heart and we do a lot of immune correlative work. And I think the reason I got so excited about this field to begin with was trying to learn why it works for some patients and why it doesn't work for other patients. So I'm a huge believer in learning from every patient that we can. So it's such a testament to the company, Agenus, who sponsored this trial to invest their time and resources into correlative studies at this phase. It's huge. So we learned a couple of things. IL-6 or interleukin 6 is a cytokine that basically has, in other tumor types, been associated with worse outcomes. And what we were interested in this group is we saw the same thing. And again, sarcomas have very, very little correlative biology that's done. We're really in infancy and understanding the microenvironment and how that milieu balances out in our tumors. So we were really excited to see again that lower peripheral interleukin 6 associated with improved overall survival. So again, kind of sorting out a group of patients that might be immunologically favorable when it comes to this type of therapy. The other thing that's important to know about sarcoma is so the other tumor types are lucky and have PD-L1 expression and the tumor is a biomarker, but we never have PD-L1 expression. We can find it in sarcomas and it can be loosely correlated with a chance of benefit with immunotherapy. But I've had patients respond that were PD-L1 negative, and I've had patients that were loaded with PD-L1 that didn't seem to make a difference. And that's not just in this study. So we saw in this trial a trend towards improved overall survival with PD-L1 expression that wasn't significant, but there was like this trend. And it's really interesting because, again, this is largely a CTLA-4 directed therapy. And so what we wondered is if PD-L1 expression is an index of sort of this underlying potential immunogenicity. And actually PD-1 works very late in the whole immune process. That's really at the very end where you've got the T cell that's facing the tumor cell and it's just activating that T cell that's already grown up and already educated and ready to go. Whereas CTLA-4 is really educating in early immune responses and expanding the T cells that have potential to kill. So I'm interested to look into this in more depth in the future to see if this is actually the biomarker for CTLA-4 directed therapy that we've been looking for, because we really don't have a great sense about that. And then the last piece just to note is that in this trial, like most others, very, very few sarcomas had high mutational burden. Everybody was very low, which reflects the population. And it's just really more encouragement than an immune cold tumor with very crappy neoantigens can still respond to immunotherapy if we get them the right agents. Shannon Westin: Yeah, I mean, I'm taking notes because we have such a struggle with this across the gynecologic tumors. I'm like, “Okay, maybe this is finally it.” So hopefully your work will go on to really inspire us across a number of solid tumors that have been traditionally cold. So, so very exciting. And I would just say for my last question, obviously, congratulations on this successful study. What do you think are the next steps for this combination in sarcomas? Dr. Breelyn Wilky: So, again, just to your point, this trial enrolled a bunch of different subtypes, and sarcomas are not the only immune cold tumor that this combo has looked really promising for, microsatellite stable colorectal cancer, ovarian cancer that was platinum refractory, non-small cell lungs. So I think the future is really bright for immune cold tumors kind of across the board. So, yes, lots of hope for not just sarcomas but in terms of our patients, I just have to be so grateful to Agenus for their interest in a rare disease. Sometimes it's hard to get that interest for a very challenging group of patients that are all heterogeneous, they are not all the same and our big clinical trials are a few hundred patients. It's just a very different environment. But they have been so supportive and involved in making sure that sarcomas are represented in their priorities. So there are ongoing discussions about what the optimal way to explore this further in sarcomas is going to be and I cannot wait to have the official plans in place. But my hope is this will not be the last that we see of these drugs for our patients. Shannon Westin: Well, I support that and my vote is on your side. So, thank you so much again, Dr. Wilky. This time just flew by. This was such a great discussion and I mean, I think it's, again, a testament to your exciting data. And thank you to all of our listeners. This has been JCO After Hours' discussion of “Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas,” published in the JCO on January 27, 2025. So be sure to check out the full manuscript. And we hope that you enjoyed this podcast. And if you want to hear more about research published in the JCO, check this out on our ASCO JCO website or wherever you get your podcasts. Have an awesome day.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Dr. Wilky Disclosures  Consulting or Advisory Role: SpringWorks Therapeutics, Deciphera, Epizyme, Adcendo, Polaris, Boehringer Ingelheim, AADi, InhibRx Research Funding: Exelixis Travel, Accommodations, Expenses: Agenus    

Many of us have been told for most of our lives that fluoride is greatly beneficial to our health. So how did we get from fluoride in the public water supply being one of history's great public health achievements to it standing trial in the court of public opinion? We invite Drs. Bina Katechia and Aadarsh Gopalakrishna from the UConn School of Dental Medicine to deliberate and render a verdict. (Dr. Bina Katechia, Dr. Aadarsh Gopalakrishna, Carolyn Pennington, Chris DeFrancesco, February 2025, studio and technical support by Ethan Giorgetti) Dr. Bina Katechia, interim chair, UConn School of Medicine Department of Pediatric Dentistry https://facultydirectory.uchc.edu/profile?profileId=Katechia-Bina Dr. Aadarsh Gopalakrishna, chair, UConn School of Medicine Division of General Dentistry https://facultydirectory.uchc.edu/profile?profileId=Gopalakrishna-Aadarsh Pediatric dentistry at UConn Health https://health.uconn.edu/dental/patient-services/pediatric-dentistry/ General dentistry at UConn Health https://health.uconn.edu/dental/ UConn School of Dental Medicine https://dentalmedicine.uconn.edu/

In this episode, Amy sits down with Ted Talk speaker, blogger, and activist, Dave deBronkhart. They delve into Dave's extraordinary journey of surviving stage 4 cancer and how his proactive approach in healthcare led to his survival and empowerment advocacy. Amy, who lives with cystic fibrosis, shares how Dave's work inspired her to take agency over her health. Together, they discuss the importance of patient empowerment, collaboration between patients and healthcare providers, and defining personal abundance beyond material success.  Tune in to learn how Dave is actively changing the culture of healthcare, creating an inspiring  patient-doctor partnership. More about Dave: Dave deBronkart, known on the internet as e-Patient Dave, is the author of the highly rated Let Patients Help: A Patient Engagement Handbook and one of the world's leading advocates for patient engagement. After beating stage IV kidney cancer in 2007 he became a blogger, health policy advisor and international keynote speaker. An accomplished speaker in his professional life before cancer, he is today the best-known spokesman for the patient engagement movement, attending over 650 conferences and policy meetings in 26 countries, including testifying in Washington for patient access to the medical record under Meaningful Use. A co-founder and chair emeritus of the Society for Participatory Medicine, e-Patient Dave has appeared in Time, U.S. News, USA Today, Wired, MIT Technology Review, and the HealthLeaders cover story “Patient of the Future.” His writings have been published in the British Medical Journal, the Patient Experience Journal,  iHealthBeat, and the conference journal of the American Society for Clinical Oncology. In 2009 HealthLeaders named him and his doctor to their annual list of “20 People Who Make Healthcare Better,” and he's appeared on the cover of Healthcare IT News and the Australian GP magazine Good Practice. Dave's TED Talk Let Patients Help went viral, and for years was in the top half of the most viewed TED Talks of all time with over a half million views; volunteers have added subtitles in 26 languages, indicating the global appeal of his message. In 2012 the National Library of Medicine announced that it's capturing his blog in its History of Medicine Division, and he was the Mayo Clinic's 2015 Visiting Professor in Internal Medicine. Connect with Dave: https://www.epatientdave.com/ https://www.ted.com/talks/dave_debronkart_meet_e_patient_dave Connect with Amy Sylvis: ⁠https://www.linkedin.com/in/amysylvis Contact Us: https://www.sylviscapital.com https://www.sylviscapital.com/webinar

In this episode featuring faculty from the United States and Europe, Aadia I. Rana, MD, and Laurence Slama, MD, PhD, discuss the subtleties of deciding among HIV treatment options in people with adherence challenges.Listen as they debate the potential risks and benefits of long-acting ART in this population, considerations for people with viremia or resistance, recommendations concerning proviral DNA genotyping, and how to interpret guidelines and provide truly patient-centered care. PresentersAadia I. Rana, MD​Professor of Medicine​Division of Infectious Diseases​University of Alabama at Birmingham Heersink School of Medicine​Birmingham, AlabamaLaurence Slama, MD, PhD​Doctor​Department of Infectious Diseases​Hôtel Dieu University Hospital​University Paris Cité​Paris, FranceSee the full program here.https://bit.ly/450Ql2xGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast channel on Apple Podcasts, Google Podcasts, or Spotify.

Dr. Jackie Sherbuk, Assistant Professor of Medicine at the Morsani College of Medicine Division of Infectious Diseases, presents this case-based review of the use of antiretroviral therapy in HIV/AIDS patients. Dr. Sherbuk begins by reviewing and available antireturovial options, including those that are considered first line. She also covers the use of antiretrovirals in special groups, including expectant mothers, elite controllers, treatment experienced patients, HBV/HIV connected patients, and patients with chronic renal insufficiency. Lastly, Dr. Sherbuk discusses the nuances of using co-formulated combinations of antiretrovirals and mentions the newer long-acting injectable preparations.

In this episode, Cristina Mussini, MD,and William R. Short, MD, MPH, FIDSA,discuss the potential role of ART in weight change among people living with HIV.Listen to their conversation on whether ART switch can lead to weight loss after weight gain and how to counsel people living with HIV on weight loss options, including lifestyle modifications and nonpharmacologic methods.PresentersCristina Mussini, MD​Director of Infectious Diseases Clinics​Professor of Infectious Diseases​University of Modena School of Medicine​Modena, ItalyWilliam R. Short, MD, MPH, FIDSA​Associate Director of the ​HIV Clinical Trials Unit​Associate Professor of Medicine​Division of Infectious Diseases​Perelman School of Medicine​University of Pennsylvania​Philadelphia, PennsylvaniaFollow along with the slides here.https://bit.ly/3RLdrETSee the full program here.https://bit.ly/450Ql2xGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast channel on Apple Podcasts, Google Podcasts, or Spotify.

Dr. Jackie Sherbuk, Assistant Professor of Medicine at the Morsani College of Medicine Division of Infectious Diseases, presents this case-based review of the use of antiretroviral therapy in HIV/AIDS patients. Dr. Sherbuk begins by reviewing and available antireturovial options, including those that are considered first line. She also covers the use of antiretrovirals in special groups, including expectant mothers, elite controllers, treatment experienced patients, HBV/HIV connected patients, and patients with chronic renal insufficiency. Lastly, Dr. Sherbuk discusses the nuances of using co-formulated combinations of antiretrovirals and mentions the newer long-acting injectable preparations.

In episode 7 we discuss the role of the gut microbiome in weight management, and how weight loss injections like Ozempic and Wegovy are inspired by the body's own hormones. Chris Damman is Clinical Associate Professor and a practising gastroenterologist at the University of Washington in the Department of Medicine/Division of Gastroenterology and editor-in-chief at Gut Bites MD.   He is former Initiative Lead of Gut Health in the Enteric and Diarrheal Diseases team at the Bill & Melinda Gates Foundation.  He holds an M.D. from Columbia University, an M.A. in Molecular Biology & Biochemistry from Wesleyan University, and is board certified in Gastroenterology.  Chris holds research interests focused on food- and microbiome-based therapeutics for metabolic disease. He is a frequent contributor to the press as an expert in gut microbiome. To connect with Chris: www.gutbites.org https://www.linkedin.com/in/chris-damman Studies/ Articles  Discussed: https://theconversation.com/your-body-already-has-a-built-in-weight-loss-system-that-works-like-wegovy-ozempic-and-mounjaro-food-and-your-gut-microbiome-220272 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02750-2/fulltext https://www.cell.com/cell/fulltext/S0092-8674(21)00754-6

In this very special episode, we are thrilled to welcome back Ben Stecher, marking his remarkable third appearance on StimBrains (you can find him previously featured on episodes #12 and #14). Today's discussion takes a profound turn as we delve into the unique collaboration between Ben and his neurologist Dr. Alfanso Fasano, who is a Professor in the Department of Medicine (Division of Neurology) at the University of Toronto. Together, they've co-authored ‘Reprogramming The Brain‘, a book that offers a new vision for the future of brain science and neuromodulation. We are very excited to delve into this voyage as seen through the eyes of both a patient navigating the complexities of Parkinson's disease and his doctor.

Research into parapsychology and the anomalous is always happening. In this brief episode, Nicolle shares some of the studies that are currently ongoing and looking for participants. Help researchers out by sharing and please consider participating!Learn more about the Rhine Research Center's studies and follow them on Facebook: https://www.facebook.com/RhineResearchCenter Two Research Opportunities announced on the Rhine's Facebook pageUniversity of West GA's imaging survey: https://ymlp.com/zXbS7y?fbclid=IwAR24xFxrg-MDCeayxtQGmmDGPafKCV0E9kugDOGUTa64wzCAu80gygIES2UUniversity of West GA distance healing study: Unveiling the Phenomenological Journey: Exploring Distant Healing Intention Practitioners' Psychosomatization of the healing relationships.University of VA, School of Medicine Division of Perceptual Studies research link: https://med.virginia.edu/perceptual-studies/participate/participate-in-research/ IONS research: https://noetic.org/science/experiments/ Follow and/or subscribe to Nicolle's new Ream page and follow along as she writes her next book! https://reamstories.com/nicollemorockSubscribe to Nicolle's newsletter, find her books, or book a healing session at https://www.nicollemorock.com/Theme music is provided by the talented Mr. Jeremy Moss http://jeremymosscomposer.com/ (Listen through the end of the podcast to hear the whole theme song.)Connect with Nicolle at www.peeppodcast.com and https://www.facebook.com/P.E.E.P.PodcastGet merchandise at https://www.teepublic.com/user/peep-podcast

You are what you eat is true for our microbiome. Chris Damman, clinical associate professor of gastroenterology and medicine at the University of Washington, discusses how to eat and live more healthily. Chris Damman is Clinical Associate Professor and practicing gastroenterologist at the University of Washington in the Department of Medicine/Division of Gastroenterology and editor-in-chief […]

In this episode, Pamela J. McShane, MD, describes the 3 pillars for nontuberculous mycobacterial (NTM) lung disease diagnosis:Clinical symptomsRadiographic evidenceMicrobiologic dataWe will also hear from a patient who details his diagnostic journey and will hear Dr. McShane discuss an illustrative clinical case.Presenter: Pamela J. McShane, MD Professor of Medicine Division of Pulmonary and Critical Care Medicine The University of Texas Health Science Center at Tyler Tyler, Texas Link to program page: https://bit.ly/3QzJo2BLink to downloadable slides: https://bit.ly/3Qh8T7G

In this episode, Charles L. Daley, MD, discusses guideline-based treatment recommendations for nontuberculous mycobacterial (NTM) lung disease, including treatment regimens for:Mycobacterium avium complexM. kansasiiM. xenopiWe will also hear from a patient who describes the use of airway clearance devices and a patient who describes his typical NTM treatment course.Finally, we hear Dr. Daley discuss a patient case with his colleagues, Shannon Kasperbauer, MD, and Pamela J. McShane, MD.Presenters:Charles L. Daley, MD​Professor of Medicine​Division of Mycobacterial and Respiratory Infections ​National Jewish Health​Denver, Colorado​Shannon Kasperbauer, MD​Associate Professor of Medicine​Division of Mycobacterial and Respiratory Infections​National Jewish Health​Denver, Colorado​Pamela J. McShane, MD​Professor of Medicine​Division of Pulmonary and ​Critical Care Medicine​The University of Texas Health Science Center at Tyler​Tyler, TexasLink to program page: https://bit.ly/3QzJo2BLink to downloadable slides: https://bit.ly/3Qh8T7G 

In this episode, Shannon Kasperbauer, MD, discusses guideline-based treatment recommendations for people with M. abscessus, including a discussion of:Macrolide resistancePredictors for disease progression2020 NTM guideline recommended treatment optionsEmerging therapiesWe will also hear from a patient who describes how she remained adherent during long courses of treatment for M. abscessus.Finally, we hear Dr Kasperbauer discuss a patient case with her colleagues, Charles L. Daley, MD, and Pamela J. McShane, MD.Presenters:Charles L. Daley, MD​Professor of Medicine​Division of Mycobacterial and Respiratory Infections ​National Jewish Health​Denver, Colorado​Shannon Kasperbauer, MD​Associate Professor of Medicine​Division of Mycobacterial and Respiratory Infections​National Jewish Health​Denver, Colorado​Pamela J. McShane, MD​Professor of Medicine​Division of Pulmonary and ​Critical Care Medicine​The University of Texas Health Science Center at Tyler​Tyler, TexasLink to program page: https://bit.ly/3QzJo2BLink to downloadable slides: https://bit.ly/3Qh8T7G

Dr. Emily Jacobs is an Associate Professor of Psychological & Brain Sciences and the director of the Ann S. Bowers Women's Health Initiative at University of California, Santa Barbara. She received her PhD in Neuroscience at the University of California, Berkeley, and her BA in Neuroscience from Smith College. Prior to UCSB, she was an instructor at Harvard Medical School and at the Department of Medicine/Division of Women's Health at Brigham & Women's Hospital.  In this episode we discuss the pioneering work of Dr. Jacobs and her group in leveraging brain imaging, computation, and endocrine approaches to deepen our understanding of the influence of sex hormones on the central nervous system across spatial and temporal scales. She discusses her group's work using structural and functional neuroimaging methods to explore how the brain changes in response to endogenous hormonal changes, such as across the menstrual cycle, during menopause, or across pregnancy, as well as to exogenous hormones via oral hormonal contraceptives. Through the Ann S. Bowers Women's Health Initiative, Dr. Jacobs and her group are working towards creating a population-level brain imaging dataset to advance our understanding of women's brain health across the lifespan.   Dr. Jacobs also shared her journey into neuroscience research, her thoughts on how science can inform public policy, and talked about her groups' efforts to improve girls' representation in STEM by partnering with K-12 groups. This work was featured in the book STEMinists: The Lifework of 12 Women Scientists and Engineers.  At OHBM 2023, Dr. Jacobs will highlight the power of sex steroid hormones and the role that they play in shaping the brain over multiple timescales, drawing attention to some of the reasons why it has taken the field so long to focus on women's brain health. Comcom Organizers: Elisa Guma and Simon Steinkamp Produced by: Alfie Wearn

This episode is sponsored by Charm Economics– data-driven solutions for digital health & MedTech businesses. Dr. Block and his guest, Dr. Ken Milne, delve into the concept of knowledge translation and the time it takes for new information to be integrated into clinical practice. They reference a famous paper that found it takes an average of 17 years for clinically relevant information to reach the patient's bedside.  However, the hosts believe that this time frame can be shortened with the help of social media and evidence-based medicine. They emphasize the importance of evidence-based medicine but also note that it should not be the only factor in decision-making. The hosts also discuss their checklist for evaluating the validity of studies and how they use their podcast to share new information with their audience. Overall, the hosts believe that shortening the time it takes for new information to be integrated into clinical practice can lead to improved patient outcomes. The episode also touches on the potential benefits of vitamin C in treating sepsis patients. One study conducted at Dr. Paul Merrick's Institution showed a significant mortality benefit in patients who were given a cocktail of thiamine, Vitamin C, and hydrocortisone. However, the study was not a randomized control trial and was before-and-after observational, leading to skepticism about the conclusions. Over the next few years, properly designed randomized control trials were conducted and found that vitamin C had no significant impact on sepsis patients. Therefore, while there was initial interest in the potential benefits of vitamin C in treating sepsis, further research has shown that it is not an effective treatment. Looking for something specific within the show? Here you go! [00:00:00] Evidence-based medicine in practice.  [00:05:27] Knowledge translation takes 17 years.  [00:07:26] Randomized control trial questions.  [00:10:59] Shared decision-making in medicine.  [00:14:53] Evidence-based medicine in emergency room.  [00:18:18] Physicians' big egos.  [00:22:20] TXA: The Duct Tape.  [00:24:01] Health interventions and cost.  [00:27:46] Subgroup analysis in studies.  [00:31:12] Epistemology and scientific bias.  [00:34:32] Vitamin C and its benefits.  [00:38:17] Losing to get better. Guest bio: Dr. Milne is a staff physician at Staff at South Huron Hospital Association in Exeter, Ontario, Canada. He has been doing medical research for over 35 years publishing on a variety of topics. Dr. Milne has been working clinically for 25 years and is an adjunct professor in the Department of Medicine (Division of Emergency Medicine) and Department of Family Medicine at the Schulich School of Medicine and Dentistry. He teaches evidence-based medicine, clinical epidemiology, critical appraisal and biostatistics at Western University in London, Ontario. Dr. Milne is passionate about skepticism and critical thinking. He is the creator of the knowledge translation project, The Skeptics' Guide to Emergency Medicine (TheSGEM). Ken is married to Barb and has three amazing children. Dr. Milne serves as a senior editor of Academic Emergency Medicine. He has no funding from the pharmaceutical or biomedical device industry. He is on faculty for the Center for Medical Education and EMRAP. Dr. Milne does partake in medical malpractice reviews and does hold a patent on a pediatric resuscitation device. Connect with Dr. Milne on his LinkedIn.  Did ya know…  You can also be a guest on our show? Please email me at brad@physiciansguidetodoctoring.com to connect.  Socials: @physiciansguidetodoctoring on FB  @physicianguidetodoctoring on YouTube @physiciansguide on Instagram and Twitter

In this episode, Marta Boffito, MD, PhD, FRCP, and Michelle Cespedes, MD, MS, discuss initial ART options, including:Recommended first-line ART options for most PWH according to DHHS, IAS-USA, EACS, BHIVA, and WHO guidelines Data for weight gain after ART initiation with different ARV classes and drugsWeight gain disparities by race and gender after ART initiationData from the RESPOND study including risk factors for weight gain and CV event risk with INSTI vs non-INSTI–based ART The impact of INSTIs on CV events in the Swiss HIV Cohort study Recommendations for ART and contraception for PWH of childbearing potential Drug–drug interactions between first-line ART and contraceptive options Guideline-recommended first-line ART options in pregnancy with a discussion of how these regimens differ from those recommended for most PWH Marta Boffito, MD, PhD, FRCP Consultant Physician Clinical Director, HIV, Sexual and Gender Health, Dermatology Chelsea and Westminster Hospital NHS Foundation Trust Imperial College London London, United Kingdom Michelle Cespedes, MD, MS Professor of Medicine Division of Infectious Disease Department of Medicine Icahn School of Medicine at Mount Sinai New York, New York Link to full program: bit.ly/3HPu4Lk

Jeffrey Reznick (The National Library of Medicine) comes on the podcast to discuss his work as Chief of the History of Medicine Division at the National Library of Medicine and his research, particularly on the 1918 influenza pandemic. The conversation begins with a survey of the National Library of Medicine, and Jeffrey briefly outlines his normal work there before moving on to the Library's multifaceted responses to Covid - including the preservation of information and ephemera. Jeffrey reflects on the connections between Covid and the 1918 influenza pandemic on multiple levels. The conversation includes multiple references to resources and tools that the Library of Medicine has been working on and making available to online users. Before wrapping up, the conversation touches upon some of the future directions for the Library of Medicine.

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-cme-ce/podcast/copd-patient-cases-reduced-lung-function  Overview: “Lung Health Updates for Primary Care Providers: Conversations with NHLBI” is a series of CME podcast episodes produced by Pri-Med in partnership with Learn More Breathe Better®, a program of the National Heart, Lung, and Blood Institute of the National Institutes of Health. In this episode looking at case studies of patients with reduced lung function, we are joined by Dr. Mihaela Stefan, a Program Officer with NHLBI's Division of Lung Diseases, and Dr. Elizabeth Oelsner, general internist and Irving Assistant Professor of Medicine at Columbia University Department of Medicine Division of General Medicine. We'll be discussing profiles of three patients with reduced lung function, including an asymptomatic smoker, a smoker with respiratory symptoms but without spirometric evidence of COPD, and a COPD patient with history suggestive of AAT deficiency. So let's begin.

Dr. Ken Milne has been working clinically as an emergency physician for 27 years and is an Associate Professor in the Department of Medicine (Division of Emergency Medicine) and Department of Family Medicine. Dr. Milne is passionate about skepticism and critical thinking. He is the creator of the knowledge translation project, The Skeptics' Guide to Emergency Medicine (TheSGEM). He teachesa evidence-based medicine, clinical epidemiology, critical appraisal and biostatistics at Western University in London, Ontario, and serves as a senior editor of Academic Emergency Medicine. He has no funding from the pharmaceutical or biomedical device industry. Citations · Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996 Jan 13;312(7023):71-2. doi: 10.1136/bmj.312.7023.71. PMID: 8555924; PMCID: PMC2349778. · Every-Palmer S, Howick J. How evidence-based medicine is failing due to biased trials and selective publication. J Eval Clin Pract. 2014 Dec;20(6):908-14. doi: 10.1111/jep.12147. Epub 2014 May 12. PMID: 24819404. · Ioannidis JP. Evidence-based medicine has been hijacked: a report to David Sackett. J Clin Epidemiol. 2016 May;73:82-6. doi: 10.1016/j.jclinepi.2016.02.012. Epub 2016 Mar 2. PMID: 26934549. · Guyatt G. Dave Sackett and the ethos of the EBM community. J Clin Epidemiol. 2016 May;73:75-81. doi: 10.1016/j.jclinepi.2016.02.008. Epub 2016 Mar 2. PMID: 26934550. · Murad MH, Asi N, Alsawas M, Alahdab F. New evidence pyramid. Evid Based Med. 2016 Aug;21(4):125-7. doi: 10.1136/ebmed-2016-110401. Epub 2016 Jun 23. PMID: 27339128; PMCID: PMC4975798. · Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ. 2003 Dec 20;327(7429):1459-61. doi: 10.1136/bmj.327.7429.1459. PMID: 14684649; PMCID: PMC300808. · Hayes MJ, Kaestner V, Mailankody S, Prasad V. Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutes. CMAJ Open. 2018 Jan 15;6(1):E31-E38. doi: 10.9778/cmajo.20170088. PMID: 29343497; PMCID: PMC5878948. · Yeh RW, Valsdottir LR, Yeh MW, Shen C, Kramer DB, Strom JB, Secemsky EA, Healy JL, Domeier RM, Kazi DS, Nallamothu BK; PARACHUTE Investigators. Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial. BMJ. 2018 Dec 13;363:k5094. doi: 10.1136/bmj.k5094. Erratum in: BMJ. 2018 Dec 18;363:k5343. PMID: 30545967; PMCID: PMC6298200. --- Support this podcast: https://anchor.fm/healingispossible/support

Dr. Michel Rathbone, MB, ChB, PhD, FRCPC obtained his medical degree from the University of Liverpool, a Ph.D. in Biochemistry from McMaster University, and a Fellowship of the Royal College of Physicians of Canada with Specialist Certification in Neurology. He is a professor in the Department of Medicine (Division of Neurology) at McMaster University. Dr. Rathbone has an active neurological practice where he consults on inpatient spinal cord injury and acquired brain injury and runs acquired brain injury outpatient clinics. He also teaches programs at McMaster in the areas of neuroscience, neurology and neuropharmacology.www.greenbankclinic.com

Dr. Jacqueline Sherbuk, Assistant Professor at the Morsani College of Medicine Division of Infectious Diseases, presents a review on several important classes of clinically significant gram-positive bacteria. Dr. Sherbuk begins by discussing Staphylococcus aureus, MRSA, and Coagulase negative Staphylococci and some of the clinical syndromes they can cause. Next, Dr. Sherbuk introduces Streptococcus pneumonia and the syndrome of invasive pneumococcal disease. Then, Group A strep pyogenes, the viridans streptococci, and the variant streptococci are related. Also presented are Enterococcus faecalis and vancomycin resistant enterococcus faecium. Lastly, Dr. Sherbuk references Corynebacterium spp., Listeria, Bacillus, and Erysipelothirx spp.

Introduction of moderator, faculty, and disclosures by Todd: ­We have an incredible discussion coming up with our moderator, Dr. Jessica Kerr, Professor and Clinical Pharmacy Specialist – Cardiometabolic at the Southern Illinois University Edwardsville School of Pharmacy in Illinois and Dr. Joanna Hudson, who is a tenured Professor in the Department of Clinical Pharmacy and Translational Science and the Department of Medicine (Division of Nephrology) at the University of Tennessee (UT) Health Science Center and a Clinical Pharmacist specializing in nephrology at Methodist Hospital in Memphis, TN. They will provide a brief overview of anemia in chronic kidney disease and highlight updates and advancements in the development of some of the emerging agents used.  If you haven't listened to the three other webinars in this learning series on anemia in chronic kidney disease, be sure to check them out at pharmacytimes.org. Outline updates and advancements in the development of HIF-PH inhibitors for anemia in chronic kidney disease.   Express the role of the pharmacist in managing anemia in CKD through early detection and coordination of care.    Guests:    Dr. Jessica Kerr PharmD Interim Associate Dean - Office of Professional and Student Affairs at Southern Illinois University Edwardsville   Dr. Joanna Hudson PharmD Professor at University of Tennessee Health Science Center Learn more about your ad choices. Visit megaphone.fm/adchoices

Introduction of moderator, faculty, and disclosures by Todd: ­We have an incredible discussion coming up with our moderator, Dr. Jessica Kerr, Professor and Clinical Pharmacy Specialist – Cardiometabolic at the Southern Illinois University Edwardsville School of Pharmacy in Illinois and Dr. Joanna Hudson, who is a tenured Professor in the Department of Clinical Pharmacy and Translational Science and the Department of Medicine (Division of Nephrology) at the University of Tennessee (UT) Health Science Center and a Clinical Pharmacist specializing in nephrology at Methodist Hospital in Memphis, TN. They will provide a brief overview of anemia in chronic kidney disease and highlight updates and advancements in the development of some of the emerging agents used.  If you haven't listened to the three other webinars in this learning series on anemia in chronic kidney disease, be sure to check them out at pharmacytimes.org. Outline updates and advancements in the development of HIF-PH inhibitors for anemia in chronic kidney disease.   Express the role of the pharmacist in managing anemia in CKD through early detection and coordination of care.    Guests:    Dr. Jessica Kerr PharmD Interim Associate Dean - Office of Professional and Student Affairs at Southern Illinois University Edwardsville   Dr. Joanna Hudson PharmD Professor at University of Tennessee Health Science Center Learn more about your ad choices. Visit megaphone.fm/adchoices

Introduction of moderator, faculty, and disclosures by Todd: ­We have an incredible discussion coming up with our moderator, Dr. Jessica Kerr, Professor and Clinical Pharmacy Specialist – Cardiometabolic at the Southern Illinois University Edwardsville School of Pharmacy in Illinois and Dr. Joanna Hudson, who is a tenured Professor in the Department of Clinical Pharmacy and Translational Science and the Department of Medicine (Division of Nephrology) at the University of Tennessee (UT) Health Science Center and a Clinical Pharmacist specializing in nephrology at Methodist Hospital in Memphis, TN. They will provide a brief overview of anemia in chronic kidney disease and highlight updates and advancements in the development of some of the emerging agents used.  If you haven't listened to the three other webinars in this learning series on anemia in chronic kidney disease, be sure to check them out at pharmacytimes.org. Outline updates and advancements in the development of HIF-PH inhibitors for anemia in chronic kidney disease.   Express the role of the pharmacist in managing anemia in CKD through early detection and coordination of care.    Guests:    Dr. Jessica Kerr PharmD Interim Associate Dean - Office of Professional and Student Affairs at Southern Illinois University Edwardsville   Dr. Joanna Hudson PharmD Professor at University of Tennessee Health Science Center Learn more about your ad choices. Visit megaphone.fm/adchoices

The "Patients and Communities Driving Research" topic was originally presented during National Minority Quality Forum's weekly webinar series. Listen now for a closer look at addressing existing disparities. Panelists: Lina Victoria Mata McMurry, MD, Vice President, Clinical & Social Research and Development, National Minority Quality Forum Megan Lockwood, MD, Assistant Professor of Medicine Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital Ana Vasquez, Patient and DC resident Bishop J. L. Carter Pastor, ARK Church Baltimore, MD Mary Stober Murray, MS PopH Vice President, Collaborative Action Networks National Minority Quality Forum (Moderator)

Podcast Series Title: The 411 on a GLP-1Podcast Series Description: Join series host Dr. Jim Gavin, Clinical Professor of Medicine at Emory University and Chief Medical Officer for Healing our Village in Atlanta, Georgia, and fellow leaders in the field of diabetes as they tackle some of the challenges we face when treating T2D. Topics of discussion include clinical inertia, as well as the mechanism of action, dosing, efficacy, and safety of a GLP-1 RA for adults with T2D.Episode Title: How to Empower Patients with T2D Knowledge and Introduce a GLP-1 RAEpisode Description: What do you need to know about a once-daily GLP-1 RA and what can you do to help your patients taking this T2D therapy? Join this multidisciplinary discussion with Jim Gavin, MD; Curtis Triplitt, PharmD; and Jeffrey Unger, MD, as they review the mechanism of action, dosing, efficacy, and safety of a once-daily GLP-1 RA for adult patients with T2D. This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.Faculty Presenters:James R. Gavin III, MD, PhDClinical Professor of Medicine, Emory UniversityChief Medical Officer, Healing Our Village, Inc.Atlanta, GeorgiaJeff Unger, MD, FAAFP, FACEDiplomate, American Board of Family PracticeAssistant Clinical Professor of Family Medicine, UC Riverside School of MedicineRiverside, CaliforniaDirector, Unger Concierge Primary Care Medical GroupRancho Cucamonga, CaliforniaCurtis L. Triplitt, PharmD, CDCES, FADCESClinical Associate Professor of Medicine Division of DiabetesUniversity of Texas Health at San AntonioTexas Diabetes Institute, part of the University Health SystemSan Antonio, Texas

Dr. Stephanie Maximous chats with Dr. Deb Banerjee and Dr. Nick Nassikas about their article,“Feasibility and Preliminary Efficacy of an Anti-racism Curriculum in an Academic, Pulmonary, Critical Care and Sleep Medicine Division."

What do you need to know about a once-daily GLP-1 RA and what can you do to help your patients taking this T2D therapy? Join this multidisciplinary discussion with Jim Gavin, MD; Curtis Triplitt, PharmD; and Jeffrey Unger, MD, as they review the mechanism of action, dosing, efficacy, and safety of a once-daily GLP-1 RA for adult patients with T2D.  This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.Faculty Presenters:James R. Gavin III, MD, PhDClinical Professor of Medicine, Emory UniversityChief Medical Officer, Healing Our Village, Inc.Atlanta, GeorgiaJeff Unger, MD, FAAFP, FACEDiplomate, American Board of Family PracticeAssistant Clinical Professor of Family Medicine, UC Riverside School of MedicineRiverside, CaliforniaDirector, Unger Concierge Primary Care Medical GroupRancho Cucamonga, CaliforniaCurtis L. Triplitt, PharmD, CDCES, FADCESClinical Associate Professor of Medicine Division of DiabetesUniversity of Texas Health at San AntonioTexas Diabetes Institute, part of the University Health SystemSan Antonio, Texas 

When we hear the word research, most of us think of innovative breakthrough treatments and technologies. But applied clinical research could not be possible without another type of research called basic science research in which scientists study the fundamental processes of the human body. In this episode, we'll learn what basic science research is and how it applies to the area of kidneys and kidney disease.   In this episode, we spoke with: Hannah Wesselman Hannah Wesselman is a PhD candidate at the University of Notre Dame studying the genetic mechanisms underlying kidney development in Dr. Rebecca Wingert's lab. Prior to her dissertation work, Hannah worked with Dr. Larissa Myaskovsky at the University of Pittsburgh Center for Research on Health Care, and their collaboration continued as Dr. Myaskovsky moved to the University of New Mexico Center for Healthcare Equity in Kidney Disease. During this time, Hannah worked directly with kidney transplant patients, and later published in CJASN on social determinants and race disparities in kidney transplant. Inspired by the strength of the kidney community, Hannah has returned to bench science in the hopes of identifying new treatment targets and has continued to connect with kidney patients through NKF advocacy. Holly Kramer, M.D., MPH Holly Kramer, M.D., MPH, is a practicing nephrologist who conducts research connecting nutrition and kidney health. Her connection to the National Kidney Foundation was inspired by her mom, who was a dialysis nurse and helped create some of the first dialysis units in Northwest Indiana. Dr. Kramer finds being on the NKF Board important, because it is the largest, patient-centered organization focusing on kidney disease. Her long-term goal is to increase national funding for kidney disease research and to heighten awareness about chronic kidney disease. Joseph V. Bonventre, M.D., PhD Dr. Bonventre is the Samuel A. Levine Distinguished Professor of Medicine and Constantine L. Hampers Distinguished Chair at Harvard Medical School and Professor of Health Sciences and Technology at the Massachusetts Institute of Technology. He is Chief of the Renal Division and Founding Chief of the Engineering in Medicine Division of the Brigham and Women's Hospital. In addition to his B.S. with distinction in Engineering Physics from Cornell, Dr. Bonventre holds M.D. and Ph.D. degrees in Biophysics from Harvard University.  He has honorary doctorate degrees from Mt. Saint Mary's College and from the Norwegian Institute of Science and Technology in Norway. He was Director of the Harvard-MIT Division of Health Sciences and Technology for 10 years.    Additional resources: Kidney Research NKF Research Connect NKF Patient Network Become an Advocate   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts!

Marijuana.  Mary Jane.  Weed. Pot.  Cannabis comes in many different names and many different forms.  Today, it has become more and more popular.  States are legalizing it for medical and recreational use, and it may be federally decriminalized soon.  Growers, dispensaries, certain health care professionals, and your run of the mill pot-head claim that it can solve and fix many medical issues…. But does it?  Our host, Noah Zimmerman, has been a daily user for the past 5 years, and reviews studies and anecdotal evidence to figure out if cannabis really is the “magical medicine” some claim it to be.  And listen to find out why he has decided to stop being a daily user! Works cited: Desmarais, A., Smiddy, S., Reddy, S., El-Dallal, M., Erlich, J., & Feuerstein, J. D. (2020). Evidence supporting the benefits of marijuana for Crohn's disease and ulcerative colitis is extremely limited: a meta-analysis of the literature. Annals of gastroenterology, 33(5), 495–499. https://doi.org/10.20524/aog.2020.0516 National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington (DC): National Academies Press (US); 2017 Jan 12. Available from: https://www.ncbi.nlm.nih.gov/books/NBK423845/ doi: 10.17226/24625 Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. (2014). Adverse health effects of marijuana use. The New England journal of medicine, 370(23), 2219–2227. https://doi.org/10.1056/NEJMra1402309 Bonn-Miller MO, Sisley S, Riggs P, Yazar- Klosinski B, Wang JB, Loflin MJE, et al. (2021) The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial. PLoS ONE 16(3): e0246990. https://doi.org/10.1371/journal. pone.0246990 Bahorik, A. L., Sterling, S. A., Campbell, C. I., Weisner, C., Ramo, D., & Satre, D. D. (2018). Medical and non-medical marijuana use in depression: Longitudinal associations with suicidal ideation, everyday functioning, and psychiatry service utilization. Journal of affective disorders, 241, 8–14. https://doi.org/10.1016/j.jad.2018.05.065 Amen, D. G. (2018, August 21). Largest brain study of 62,454 scans identifies drivers of brain aging. Largest Brain Study of 62,454 Scans Identifies Drivers of Brain Aging | Journal of Alzheimer's Disease. Retrieved May 22, 2022, from https://www.j-alz.com/content/largest-brain-study-62454-scans-identifies-drivers-brain-aging Lisano, J. K., Smith, J. D., Mathias, A. B., Christensen, M., Smoak, P., Phillips, K. T., Quinn, C. J., & Stewart, L. K. (2019). Performance and Health-Related Characteristics of Physically Active Males Using Marijuana. Journal of strength and conditioning research, 33(6), 1658–1668. https://doi.org/10.1519/JSC.0000000000002238

Vikesh Ramsunder – Outgoing CEO, Clicks

Originally Recorded Live On August 26, 2021 The spread of the COVID-19 delta variant continues to alter our daily lives both at home and at work, and it's placing a tremendous financial burden on many families. This live event addressed your questions on how to stay safe and protected given the changing information around mask guidelines and booster shots. It also covered how to navigate a changing workplace and how to find financial help and assistance. The experts: Steven C. Johnson, M.D. Professor of Medicine Division of Infectious Diseases University of Colorado School of Medicine Anschutz Medical Campus Multidisciplinary Center on Aging Lee Baker Owner and President Apex Financial Solutions Nancy LeaMond Special Guest Executive Vice President Chief Advocacy and Engagement Officer, AARP

Originally Recorded Live on August 26, 2021 The spread of the COVID-19 delta variant continues to alter our daily lives both at home and at work, and it's placing a tremendous financial burden on many families. This live event addressed your questions on how to stay safe and protected given the changing information around mask guidelines and booster shots. It also covered how to navigate a changing workplace and how to find financial help and assistance. The experts: Steven C. Johnson, M.D. Professor of Medicine Division of Infectious Diseases University of Colorado School of Medicine Anschutz Medical Campus Multidisciplinary Center on Aging Lee Baker Owner and President Apex Financial Solutions Nancy LeaMond Special Guest Executive Vice President Chief Advocacy and Engagement Officer, AARP

As pandemic restrictions begin to loosen in many communities across the country, patients with chronic lymphocytic leukemia (CLL) face greater uncertainty in this “new normal” due to their increased risk for contracting COVID-19 and a lower response rate to the vaccine.   On this episode, three clinicians discuss their experiences with difficult conversations on the relative risks and benefits around treatment decisions, engaging the entire cancer team in shared decision-making with patients, accessing emerging evidence and data in this rapidly evolving environment, and the potential impact of variant exposure on this unique patient population.   Guests: John N. Allan, MD Assistant Professor of Medicine Division of Hematology and Medical Oncology Weill Cornell Medicine New York, NY   Mark J. Fesler, MD Director, Bone Marrow Transplant Program, Associate Professor of Internal Medicine Division of Hematology and Oncology Saint Louis University St. Louis, MO   Susannah P. Friemel, MD  Owner/President Iowa Cancer Specialists, PC Davenport, IA    Related Content [VIDEO PODCAST] Ep 02: Myeloma Care Strategies & COVID-19 Trending Now in Cancer Care Resources Telehealth at Its Best: Transitioning a Comprehensive Psychosocial Program to a Virtual Format Telemedicine and Cancer Care: Today's Learnings for a Post-Pandemic World ACCC Telehealth Resources [PODCAST] Episode 28: Telehealth & Genetics During COVID-19 [PODCAST] Mini-Podcast: Staff Resiliency During COVID-19

Charlie Brennan and Amy Marxkors talk about a man witnessing a murder and being on hold for 10 minutes. Dr. Steven Lawrence, Professor of Medicine Division of Infectious Diseases Washington University School of Medicine joins the show dispelling the vaccine myths. See omnystudio.com/listener for privacy information.

Drs. Charles Vega and Aima A. Ahonkha discuss ways we can address the COVID-19 health outcome disparities. Topics: Real COVID-19 patient stories COVID-19 health outcomes based on ethnicity and socioeconomic status How social determinants of health determine COVID-19 risk Treating hospitalized and ambulatory patients Post-test for CME/CE credit: https://covid19.dkbmed.com/multispecialty/6-18-21-episode/eval Access our resource center, download webinar slides, and claim credit at https://covid19.dkbmed.com/multispecialty Presenting faculty: Charles Vega, MD, FAAFP Health Sciences Clinical Professor UC Irvine Department of Family Medicine Assistant Dean for Culture and Community Education UC Irvine School of Medicine Director, UC Irvine Program in Medical Education for the Latino Community Irvine, CA Aima A. Ahonkhai, MD, MPH Assistant Professor of Medicine Division of Infectious Diseases Vanderbilt University Medical Center See acast.com/privacy for privacy and opt-out information.

Podcast:  Not Just for Kids: Management of the Adult Congenital Disease Population  Evaluation and Credit:  https://www.surveymonkey.com/r/MedChat28   Target Audience             This activity is targeted toward primary care adult and pediatric specialties.    Statement of Need As patients with congenital heart disease are living longer into adulthood, ongoing management of the CHD is critical. Patients with complex CHD are at greater risk for premature death and therefore management of these patients is critical to help improve patient outcomes.   Objectives At the conclusion of this offering, the participant will be able to: Define the epidemiology of adult congenital heart disease (ACHD) within the United States. Describe common medical complications in ACHD and the multidisciplinary care required to manage those complications. Discuss how changes in pediatric cardiology and adult congenital care have shifted the mortality outcomes in ACHD. Moderator Erin Frazier, M.D. Pediatrician Norton Children's Medical Group – Broadway   Speaker Melissa L. Perrotta, MD, FAAP Co-Medical Director of Adult Congenital Heart Disease Assistant Professor of Pediatrics The University of Louisville School of Medicine Division of Pediatric Cardiology   Moderator, Speaker and Planner Disclosures  The speaker, moderator and planners for this activity have no potential or actual conflicts of interest to disclose.     Commercial Support  There was no commercial support for this activity.   Physician Credits  American Medical Association   Accreditation Norton Healthcare is accredited by the Kentucky Medical Association to provide continuing medical education for physicians.   Designation Norton Healthcare designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.   Date of Original Release |June 2021 Course Termination Date | June 2023 Contact Information | Center for Continuing Medical Education; (502) 446-5955 or cme@nortonhealthcare.org     Resources for Additional Study    2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines https://pubmed.ncbi.nlm.nih.gov/30586767/   General principles of heart failure management in adult congenital heart disease https://pubmed.ncbi.nlm.nih.gov/31788738/   Changing mortality in congenital heart disease https://pubmed.ncbi.nlm.nih.gov/20863956/

On today’s episode of the Faculty Factory Podcast, Kimberly A. Skarupski, PhD, MPH, discusses a dilemma she calls “Competent Person Syndrome.” This is an issue facing many highly productive people in academic medicine who find themselves immersed in extra work as a direct result of their reliability and competence.   First and foremost it is important to remember that this is a blessing. It is essentially a good problem to have, although it is a problem nonetheless. If you are facing this common issue in academic medicine, there are strategies for overcoming it as Dr. Skarupski outlines on today's show. Dr. Skarupski has hosted the Faculty Factory Podcast since its inception in 2019. At Johns Hopkins Medicine in Baltimore, she serves as: Senior Associate Dean for Faculty Development, Office of Faculty Development Professor, Department of Medicine (Division of Geriatric Medicine and Gerontology) Professor, Epidemiology, Bloomberg School of Public Health

Is the vaccine safe? Was it rushed through development? How about for pregnant mothers? Children? Do we all need it? What if I'd rather just get Covid than the vaccine? Michelle Barron, MD, the Senior Medical Director at UC Health and Professor of Medicine (Division of Infectious Diseases) was kind enough to make herself available to answer every question we posed. She helps to separate reality from all the claims we are hearing about the vaccine in a very relatable way.For more information about the Catalyst Community, earning your health & wellness coaching certification, the annual Rocky Mountain Coaching Retreat & Symposium and much more, please see https://www.catalystcoachinginstitute.com/ or reach out to us Results@CatalystCoachingInstitute.com If you'd like to share the Be A Catalyst! message in your world with a cool hoodie, t-shirt, water bottle stickers and more (100% of ALL profits go to charity), please visit https://teespring.com/stores/be-a-catalyst

Faculty Factory Podcast producer Casey Callanan, MBA interviews Kimberly A. Skarupski, PhD, MPH on today's milestone 100th episode. Did you know the first ever episode of this podcast was lost? Dr. Skarupski and Mr. Callanan discuss that story and the many lessons learned from the first 100 episodes of this show. Dr. Skarupski is host of the Faculty Factory Podcast and serves as Associate Dean for Faculty Development in the Office of Faculty Development and Associate Professor of Medicine (Division of Geriatric Medicine and Gerontology) in the School of Medicine at Johns Hopkins University. She is also Associate Professor of Epidemiology in the Bloomberg School of Public Health.

When she was just 8 years old, Dr. Saskia Popescu's step-mother handed her a copy of The Hot Zone: The Terrifying True Story of the Origins of the Ebola Virus. That simple act kicked off a string of events that would positively impact thousands of lives. At TIPS, we believe that one person can make a difference and everyone should try. Sometimes that person becomes a renowned infectious diseases epidemiologist and infection preventionist who specializes in biopreparedness, biosecurity, and pandemic response, and guides hospitals and businesses safely through a pandemic, like Dr. Popescu. Other times they make a difference simply by opening the mind of a child to the great possibilities of the world. Both matter.   What's it really like on the front-lines of healthcare? Dr. Popescu was on the front-lines as an infection preventionist long before the COVID-19 pandemic. And she, like many in the healthcare industry, was already running beyond capacity. Infection Prevention efforts are notoriously under-funded and under-prioritized by hospitals. Dr. Popescu tells us that she's “never seen a fully staffed infection prevention department.” Similarly, doctors and nurses were already struggling with an epidemic of clinician burnout. To truly understand the context of what it's like out there, we must remember that everything our front-line workers are dealing with now is in addition to that existing burden. Dr. Popescu tells us how this feels, how she and her colleagues are dealing with it, and how their hospitals can help. The need, Dr. Popescu tells us, goes way beyond providing access to personal protective equipment (PPE). Some hospitals are smartly supporting their staff with child care, mental health support, meal delivery, and other non-work-related services that go a long way towards helping their teams cope with the pressure.   The challenges of scientific communication Dr. Popescu has been recognized for her communication efforts around the pandemic. In her view, the U.S. has struggled to translate nuanced CDC guidance into actual application, especially when working with people unfamiliar with the science. This is particularly true when dealing with the public. Dr. Popescu shares a few lessons learned through this experience that can and should be improved upon going forward.   We did a poor job of informing the public that guidance was likely to change. We're dealing with a novel virus, and our experts are learning on the fly in unfavorable conditions. It makes sense that things would change, but it also makes sense that people would react poorly if they were not prepared for that change. The statistics and measures we are focused on may not be the most effective for helping the public understand what's going on. We focus on positivity rates, death rates, and ICU bed counts, but little on what's happening outside of the ICU and provide no breakdowns in terms of disease severity.   We also get into the need to account for politics in future communications efforts and much more. Surely, the communications lessons of the COVID-19 pandemic will be dissected for years to come.   Historical Lessons Dr. Popescu also takes us through comparative lessons from past pandemics. The lessons we're learning today can and should be combined with those past experiences to make our next response that much more effective. We can even look to the experiences of dominant nation-states of the past like Rome. The fall of Rome is a complex topic with many factors, but infectious disease certainly contributed to its demise. Dr. Popescu tells us that “disease has a big impact on critical infrastructure and can be very destabilizing”. That is evident today, and we'd be wise not to ignore the challenges that followed these events of the past.   The Path Forward The bulk of our efforts today should be focused on saving lives, supporting healthcare workers, distributing vaccines, and ending this pandemic. However, it's never too early to begin extracting our lessons and planning for the future. Coming out of this, Dr. Popescu says, “I hope that from the top-down, from the bottom-up, we all are much more cognizant of global health security.” That means looking not just at infection control, but antimicrobial resistance testing, lab capacity, healthcare worker capacity, and more. And this can't be a fleeting interest where we throw a bunch of money at the problem and think we're handling it. Instead, we need a sustained, methodical approach with clear metrics for success.   This is a wonderfully thoughtful and thorough discussion on one of the most important topics of our time. I hope you get as much out of it as we did.   Dr. Saskia Popescu Saskia Popescu is an infectious disease epidemiologist and Senior Infection Preventionist in Phoenix, Arizona. She holds academic appointments at the University of Arizona and George Mason University, where she lectures on biopreparedness, and pandemic and outbreak response. Since the start of the COVID-19 pandemic, she's worked to prepare for and mitigate the spread of the disease. She has been recognized for her communication efforts around the pandemic, as well as her work on the front lines. Dr. Popescu holds a PhD in Biodefense from George Mason University, a Masters in Public Health with a focus on infectious diseases, and a Masters of Arts in International Security Studies, from the University of Arizona. Dr. Popescu is an Alumni Fellow of the Emerging Leaders in Biosecurity Initiative (ELBI) at the Johns Hopkins Bloomberg School of Public Health, Center for Health Security. She currently serves as a member of the Federation of American Scientists (FAS) Coronavirus Taskforce and is a member of the Committee on Data Needs to Monitor Evolution of SARS-CoV-2 within the Health and Medicine Division of the National Academies of Sciences, Engineering, and Medicine (NASEM).  Follow Dr. Popescu on Twitter (@SaskiaPopescu) Read Dr. Popescu's bio on the George Mason university biodefense program website   Links and Resources ‘Long-haul' covid-19 complications are real. I faced similar problems after surviving Ebola. by DR. Craig Spencer This is the NHS video Dr. Popescu mentioned: https://twitter.com/SaskiaPopescu/status/1329070401834475522

Daniel Mendoza -- professor, Department of Atmospheric Sciences, The Department of City & Metropolitan Planning and, The School of Medicine Division of Pulmonary University of Utah -- joins Lee to explain a new study on school absences in Salt Lake City as it relates to bad air days. See omnystudio.com/listener for privacy information.

Guest: Dr. Arya M. Sharma, Founder of Obesity Canada & Professor - Dept. of Medicine - Division of Endocrinology & Metabolism - University of Alberta.

Dr. Jeanne Marrazzo is the director of the UAB School of Medicine Division of Infectious Diseases. She joins the Reckon Interview to discuss the possibility of returning to schools, football, Alabama's mask policy and when we can expect a publicly available vaccine. See acast.com/privacy for privacy and opt-out information.

Aiming to better understand the efficacy of public health messaging in a pandemic, a team of Penn State researchers designed and deployed an unusually open-ended survey that has been translated into 23 languages and reached more than 73 countries. This episode recorded via Zoom on May 20, 2020.Relevant Links:Penn State College of Medicine COVID-19 SurveyThe College of Healthcare Information Management Executives (CHIME)CDC Coronavirus ResourcesGuests:Robert P. Lennon, MD, JD – Associate Professor, Department of Family and Community Medicine; Associate Professor, Penn State LawLauren J. Van Scoy, MD – Associate Professor, Department of Medicine Division of Pulmonary, Allergy and Critical Care Medicine; Associate Professor, Department of Humanities; Associate Professor, Department of Public Health SciencesCletis Earle, MS, CHCIO – Chief Information Officer, Penn State HealthRussell Branzell, CHCIO, FCHIME, FACHE, FHIMSS – Chief Executive Officer and President, College of Healthcare Information Management Executives (CHIME)

Dr. Onyinye Iweala is a professor of medicine in the Division of Rheumatology, Allergy & Immunology at the University of North Carolina School of Medicine whose expertise lies in environmental allergies, including allergic rhinitis, chronic hives, and food allergies. She joins the show to talk about a number of interesting topics, such as: What factors might be causing or contributing to a food allergy epidemic in developed countries The relationship between microbiota and food allergy, allergic rhinitis, and chronic sinusitis Hypotheses as to why some food allergies can be outgrown by a certain percentage of those affected, and why others cannot How the new and only FDA-approved treatment for food allergy works What happens physiologically during an alpha-gal allergy As a junior in college, Dr. Iweala took her first basic immunology class and pretty much knew that that was the path she wanted to pursue as a doctor. Not only did she find it complicated and fascinating, but also very relevant to human health. In recent years, food allergy has been on the rise, particularly in industrial countries like the U.S. This has caused concern for many people, especially since there has only very recently been a food allergy treatment on the market. Dr. Iweala discusses how this new drug functions in the body, and how it is based on the principles of oral immunotherapy.  She also explains the standard understanding of IgE-mediated allergy responses, and how a non IgE-mediated allergy response prompted by an alpha-gal allergy is unique and challenging to detect. She touches on a number of other interesting subjects, such as how multiple food allergies in a single person might be treated, the goal of recent and ongoing studies in the field, and much more.

On this Advancing Health podcast, AHA’s Akin Demehin, director of policy, speaks to Colleen Kraft, M.D., associate professor in the Department of Medicine Division of Infectious Diseases at Emory University, about novel coronavirus (COVID-19). Kraft was a physician leader during the West African Ebola outbreak and shares her experience, what this new outbreak could look like, and how hospitals can prepare.

The Scott Thompson Show Podcast Dr. Donald C. Vinh, of McGill joined Scott to discuss the new coronavirus, and how the virus compares to SARS and the Flu. Guest: Dr. Donald C. Vinh, MD, FRCP(C), Director, Infectious Disease Susceptibility Program Associate Professor, FRQS Clinician-Scientist, Dept of Medicine (Division of Infectious Diseases; Division of Allergy & Clinical Immunology), Dept of Medical Microbiology; Dept of Human Genetics , McGill University. Read more here: https://globalnews.ca/news/6484892/coronavirus-international-health-emergency-who/ - The B.C. Premier John Horgan has conceded defeat in the legal battle against TransMountain. And what is happening with the other pipeline project B.C. is embroiled in? Guest: Marvin Ryder., Business Professor, DeGroote School of Business, McMaster University - Has NORAD (the North American Aerospace Defense Command) aged and become outdated? A Canadian officer says that the agency is incapable of detecting  Russian bombers in time.Guest: David Harris, Insignis Strategic Group. Terrorism expert  

Erika Ebbel Angle received her Ph.D. in Biochemistry in 2012 from Boston University School of Medicine. She holds a B.S. from the Massachusetts Institute of Technology. In 2002 Erika founded Science from Scientists, an award-winning National nonprofit focused on improving Science, Technology, Engineering and Math (STEM) attitudes and aptitudes for children aged 9-13. She is also the co-founder and Director of Education for Robots In Service of the Environment (RSE), a non-profit organization whose mission is to apply robotic solutions to help solve environmental challenges. She is a member of the MIT visiting committee for the Dean of Undergraduate Education and is an Advisory Board member for the Ron Burton Training Village. She is also a STEM speaker for the U.S. Speaker Program at the U.S. Department of State. In 2018 she was awarded the Young Alumni award by Boston University. In 2017 she was the recipient of the Distinguished Alumni Award from Boston University School of Medicine Division of Graduate Medical Sciences. In 2014 the Boston Business Journal selected her as one of the 40 Under 40 business and civic leaders who are making a major impact in their respective fields in the Boston area. Her accomplishments have also been recognized by the Greater Boston Chamber of Commerce’s Pinnacle Awards for Emerging Executive. In 2013 the Boston Chamber of Commerce selected her as one of the Ten Outstanding Young Leaders in Boston. Selected by L’Oreal Paris as a 2007 Woman of Worth for her work with Science from Scientists, Erika has been featured on Lifetime TV and Nova Science Now on The Secret Lives of Scientists and Engineers. She is the host of The Dr. Erika Show, an educational science TV show for children. Erika served as a Commissioner for the MA Commission on the Status of Women. Erika was Miss Massachusetts 2004 in the Miss America Scholarship program. Outside of work, Erika enjoys SCUBA diving, skiing and, a graduate of the San Francisco Conservatory of Music, continues her lifelong passion for classical piano. She is married to Colin Angle, CEO of iRobot. What you will learn from this episode: 1) How a simple blood test can give you insight into your gut health. 2) What is the metabolome and why it is important? 3) Are stool tests good enough to teach us about our gut health? 4) How you can improve your fitness performance but learning about your gut health 5) What interventions you can make to improve your health and longevity How to learn more about our guest: Full Bio: https://ixcela.com/team-bios/erika-angle-phd.html Connect with Erika ● Blog: Erika Ebbel Angle ● LinkedIn: Erika Ebbel Angle ● Twitter: @DoctorErika A special thank you: As a special thank you for listening to this episode, Ixcela has been so kind as to give us a discount code which you can use to get a 10% discount. Go to ixcela.com and use the code “IxcelaWellness10” to check it out! Please enjoy, share, rate and review our podcast and help us bring the message about precision health care to the world!

Dr. Michael Lanspa sits down with Dr. Seppo Rinne to discuss burnout from the perspectives of pulmonary, critical care, and sleep medicine division directors.

Dr. Suzet McKinney, the CEO and Executive Director of the Illinois Medical District (IMD), and Jenny Han, Skender’s Director of Healthcare Design, continue their conversation from Future Built Episode 5 with a focus on career growth, ambition, and mentorship. In her work with the IMD, one of the largest urban medical districts in the United States, and West Side United, a collaboration working to build community health and economic wellness on Chicago’s West Side, Suzet follows the mantra “Go big or go home.”Tune in to hear the advice Suzet and Jenny give to young women that is applicable to anyone looking to achieve more in their work and advance professionally. And listen through to the end for Suzet’s answer to the question on many people’s minds: Will she ever run for office? About Suzet McKinneyDr. Suzet M. McKinney currently serves as CEO/Executive Director of the Illinois Medical District. She is the former Deputy Commissioner of the Bureau of Public Health Preparedness and Emergency Response at the Chicago Department of Public Health (CDPH), where she oversaw the emergency preparedness efforts for the Department and coordinated those efforts within the larger spectrum of the City of Chicago’s Public Safety activities, in addition to overseeing the Department’s Division of Women and Children’s Health.Dr. McKinney has earned a reputation as an experienced, knowledgeable public health official with exceptional communication skills. She has served as an on-camera media expert on emergency issues including biological and chemical threats, natural disasters, pandemic influenza, and climate-related emergencies. A sought-after expert in her field, she has also provided support to the U.S. Department of Defense’s, Defense Threat Reduction Agency, lending subject matter expertise in biological terrorism preparedness to the country of Poland.Dr. McKinney serves on the Board of Directors for Susan G. Komen Chicago, Thresholds, and the African-American Legacy of the Chicago Community Trust. Dr. McKinney is Co-Chair of the National Academies of Science, Engineering and Medicine (NASEM), Health and Medicine Division’s Forum on Medical and Public Health Preparedness for Disasters and Emergencies and is a member of the NASEM Board on Health Sciences Policy. She also serves on the Science and Security Board for the Bulletin of the Atomic Scientists, the Board of Scientific Counselors for the U.S. Centers for Disease Control, Office of Public Health Preparedness and Response, as well as the Federal Emergency Management Agency’s (FEMA) National Advisory Council (NAC). In academia, Dr. McKinney serves as an Instructor in the Division of Translational Policy and Leadership Development at Harvard University’s T.H. Chan School of Public Health and as Adjunct Assistant Professor of Health Policy and Administration at the University of Illinois at Chicago School of Public Health. Additionally, she serves as a mentor for the Biomedical Sciences Careers Project, also at Harvard University. She is the co-author of the text: Public Health Emergency Preparedness: Practical Solutions for the Real World (2018), and was named one of Chicago’s Notable Women in Healthcare (2018 and 2019).Dr. McKinney holds her Doctorate degree from the University of Illinois at Chicago School of Public Health. She received her Master of Public Health degree (Health Care Administration) and certificates in Managed Care and Health Care Administration from Benedictine University in Lisle, IL.

Dr. Eric Small, Professor of Medicine; Urology; and Chief, Department of Medicine/Division of Hematology/Oncology, UCSF. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 34965]

Dr. Eric Small, Professor of Medicine; Urology; and Chief, Department of Medicine/Division of Hematology/Oncology, UCSF. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 34965]

Dr. Eric Small, Professor of Medicine; Urology; and Chief, Department of Medicine/Division of Hematology/Oncology, UCSF. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 34965]

Dr. Eric Small, Professor of Medicine; Urology; and Chief, Department of Medicine/Division of Hematology/Oncology, UCSF. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 34965]

Dr. Eric Small, Professor of Medicine; Urology; and Chief, Department of Medicine/Division of Hematology/Oncology, UCSF. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 34965]

Dr. Eric Small, Professor of Medicine; Urology; and Chief, Department of Medicine/Division of Hematology/Oncology, UCSF. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 34965]

Dr. Eric Small, Professor of Medicine; Urology; and Chief, Department of Medicine/Division of Hematology/Oncology, UCSF. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 34965]

Dr. Eric Small, Professor of Medicine; Urology; and Chief, Department of Medicine/Division of Hematology/Oncology, UCSF. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 34965]

The Illinois Medical District (IMD), one of the largest urban medical districts in the United States, is a 560-acre region of Chicago that includes medical research facilities, labs, a biotech business incubator, universities, raw land development areas, four hospitals and more than 40 healthcare related facilities. Dr. Suzet McKinney, the CEO and Executive Director of the IMD, is a seasoned public health expert in the fields of emergency preparedness and natural disasters. She sits down with Skender Director of Healthcare Design Jenny Han to share more about how she got her start in public health and what led her from working on the Ebola outbreak to running the IMD. Learn more about the IMD and an exciting new initiative the IMD is involved with, West Side United – a collaboration working to build community health and economic wellness on Chicago’s West Side. About Suzet McKinneyDr. Suzet M. McKinney currently serves as CEO/Executive Director of the Illinois Medical District. She is the former Deputy Commissioner of the Bureau of Public Health Preparedness and Emergency Response at the Chicago Department of Public Health (CDPH), where she oversaw the emergency preparedness efforts for the Department and coordinated those efforts within the larger spectrum of the City of Chicago’s Public Safety activities, in addition to overseeing the Department’s Division of Women and Children’s Health.Dr. McKinney has earned a reputation as an experienced, knowledgeable public health official with exceptional communication skills. She has served as an on-camera media expert on emergency issues including biological and chemical threats, natural disasters, pandemic influenza, and climate-related emergencies. A sought-after expert in her field, she has also provided support to the U.S. Department of Defense’s, Defense Threat Reduction Agency, lending subject matter expertise in biological terrorism preparedness to the country of Poland.Dr. McKinney serves on the Board of Directors for Susan G. Komen Chicago, Thresholds, and the African-American Legacy of the Chicago Community Trust. Dr. McKinney is Co-Chair of the National Academies of Science, Engineering and Medicine (NASEM), Health and Medicine Division’s Forum on Medical and Public Health Preparedness for Disasters and Emergencies and is a member of the NASEM Board on Health Sciences Policy. She also serves on the Science and Security Board for the Bulletin of the Atomic Scientists, the Board of Scientific Counselors for the U.S. Centers for Disease Control, Office of Public Health Preparedness and Response, as well as the Federal Emergency Management Agency’s (FEMA) National Advisory Council (NAC). In academia, Dr. McKinney serves as an Instructor in the Division of Translational Policy and Leadership Development at Harvard University’s T.H. Chan School of Public Health and as Adjunct Assistant Professor of Environmental and Occupational Health Sciences at the University of Illinois at Chicago School of Public Health. Additionally, she serves as a mentor for the Biomedical Sciences Careers Project, also at Harvard University. She is the co-author of the new text: Public Health Emergency Preparedness: Practical Solutions for the Real World (2018), and was named one of Chicago’s Notable Women in Healthcare (2018).Dr. McKinney holds her Doctorate degree from the University of Illinois at Chicago School of Public Health. She received her Master of Public Health degree (Health Care Administration) and certificates in Managed Care and Health Care Administration from Benedictine University in Lisle, IL.

Jennifer Price, MD, Associate Professor of Medicine Division of Gastroenterology from UCSF. Series: "UCSF Transplant Update" [Health and Medicine] [Show ID: 34385]

Jennifer Price, MD, Associate Professor of Medicine Division of Gastroenterology from UCSF. Series: "UCSF Transplant Update" [Health and Medicine] [Show ID: 34385]

Jennifer Price, MD, Associate Professor of Medicine Division of Gastroenterology from UCSF. Series: "UCSF Transplant Update" [Health and Medicine] [Show ID: 34385]

Jennifer Price, MD, Associate Professor of Medicine Division of Gastroenterology from UCSF. Series: "UCSF Transplant Update" [Health and Medicine] [Show ID: 34385]

This special episode of Tangazo is dedicated to Charlotte Ottley. Charlotte is a public relations consultant and long time friend of host Hank Thompson. She is in urgent need of a kidney donor. We are joined by Larry D. Bonds, former heart transplant recipient and founder of the "Larry D. Bonds 4 Life Foundation", as well as Dr. Will Ross, Professor at Washington University School of Medicine-Division of Nephrology, specializing in kidney disease. Dr. Ross answers our questions via phone. This episode is very informative, while also raising awareness for ourselves and most importantly Charlotte Ottley!

Editor-in-chief of JCMS, Dr Kirk Barber speaks with Dr Afsaneh Alavi, a co-author of the study that aimed to systematically review the published evidence on the treatment of ulcerated hemangiomas, focusing on wound healing as the outcome of interest. Dr Alavi is a clinical dermatologist and Assistant Professor in the Faculty of Medicine (Division of Dermatology) at the University of Toronto.

Editor-in-chief of JCMS, Dr Kirk Barber speaks with Dr Afsaneh Alavi, a co-author of the study that aimed to systematically review the published evidence on the treatment of ulcerated hemangiomas, focusing on wound healing as the outcome of interest. Dr Alavi is a clinical dermatologist and Assistant Professor in the Faculty of Medicine (Division of Dermatology) at the University of Toronto.

The University of New Mexico’s Michael Haederle talks with UNM’s School of Medicine Division of Physical Therapy’s Division Chief and Associate Professor Dr. Beth Moody Jones about her personal journey in the field and the world of physical therapy.

Dr. Christopher Frank, Associate Professor, Department of Medicine, Division of Geriatric Medicine Queen's University talks about seniors using pot when it's legal, but the frail should be cautious.

Shadia Jalal, MD, Assistant Professor of Clinical Medicine Department of Medicine Division of Hematology/Oncology Indiana University School of Medicine, presents a self-evaluation question from an ASCO University course focusing on the treatment of non-small cell lung cancers.

The Child and Adolescent Psychiatry Center at St. Louis Children's Hospital specializes in the diagnosis and the treatment of disorders of emotion, cognition and/or behavior affecting children from infancy to age 21.With our telephone consultation service, primary care providers seeking advice in the management of acute and chronic pediatric behavioral health disorders have direct access to speak with a Washington University pediatric psychiatrist by calling Children's Direct at 800.678.HELP (4357).Ginger Nicol, MD discusses ways the psychiatrists from the Washington University School of Medicine Division of Child and Adolescent Psychiatry, combined with the support services of our Center provides patients and families with the expertise and resources for comprehensive evaluation and treatment.

Chris Freise, MD Professor of Surgery, Division of Transplantation, and Brian Lee, MD, Assistant Clinical Professor of Medicine’ Division of Transplantation, UCSF. Series: "UCSF Transplant Update" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 31129]

Chris Freise, MD Professor of Surgery, Division of Transplantation, and Brian Lee, MD, Assistant Clinical Professor of Medicine’ Division of Transplantation, UCSF. Series: "UCSF Transplant Update" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 31129]

In episode 51 of MicrobeWorld Video, filmed at the American Association for the Advancement of Science Meeting in Washington, D.C., on February 18, 2011, Dr. Stan Maloy talks with David Relman, M.D., Thomas M. and Joan C. Merigan Professor, Department of Medicine - Division of Infectious Diseases, and Department of Microbiology & Immunology in the Stanford University School of Medicine.Maloy and Relman discuss microbial flora in the mouth and gut and why they are important for human health. They explore the impact of antibiotics and probiotics on the community of microbes in the gut and their health implications both negative and positive. Lastly they look at the future of probiotics in personalized medicine and the potential for individualized treatment based on the uniqueness of a person's gut flora. Don't miss an episode of MicrobeWorld Video. Subscribe for free using iTunes or help support our work by purchasing the MicrobeWorld podcast application for iPhone and Android devices in the iTunes or Android app stores.

In episode 51 of MicrobeWorld Video, filmed at the American Association for the Advancement of Science Meeting in Washington, D.C., on February 18, 2011, Dr. Stan Maloy talks with David Relman, M.D., Thomas M. and Joan C. Merigan Professor, Department of Medicine - Division of Infectious Diseases, and Department of Microbiology & Immunology in the Stanford University School of Medicine.Maloy and Relman discuss microbial flora in the mouth and gut and why they are important for human health. They explore the impact of antibiotics and probiotics on the community of microbes in the gut and their health implications both negative and positive. Lastly they look at the future of probiotics in personalized medicine and the potential for individualized treatment based on the uniqueness of a person's gut flora. Don't miss an episode of MicrobeWorld Video. Subscribe for free using iTunes or help support our work by purchasing the MicrobeWorld podcast application for iPhone and Android devices in the iTunes or Android app stores.

In episode 51 of MicrobeWorld Video, filmed at the American Association for the Advancement of Science Meeting in Washington, D.C., on February 18, 2011, Dr. Stan Maloy talks with David Relman, M.D., Thomas M. and Joan C. Merigan Professor, Department of Medicine - Division of Infectious Diseases, and Department of Microbiology & Immunology in the Stanford University School of Medicine.Maloy and Relman discuss microbial flora in the mouth and gut and why they are important for human health. They explore the impact of antibiotics and probiotics on the community of microbes in the gut and their health implications both negative and positive. Lastly they look at the future of probiotics in personalized medicine and the potential for individualized treatment based on the uniqueness of a person's gut flora.